Announcement of Joint Research Agreement with Nagoya University for Spinal Cord Injury

Tokyo, March 5, 2020–Gene Techno Science Co., Ltd. (“GTS”) executed ajoint research agreement (“this agreement”) with Nagoya University for a development of new therapyfor spinal cordinjury.

1.Purpose of this agreement

Spinal cord injury is a motor and sensory dysfunction due tocentral nerve damagesin the spinal cord mainly caused bytraffic or sport accidents.Since the self-regenerationcapacity of central nervesis extremely lower thanthat of peripheral nerves, patients with spinal cord injuryhave to live with life-long disabilitiessuch as walking difficulty and sensory paralysis.As the functional recovery achieved by rehabilitationislimited,the development of new therapy has beenlong-awaited. Stem cell therapy is considered as a promisingcandidateand many researchresults have been reported.In particular, stem cells from human exfoliated deciduous teeth (“SHED”) have excellent capabilitiesof neuronal protectionand regeneration which could prevent functional declinesor restoreneuronalfunctionsin spinal cord injury.

Department of Neurosurgeryin Nagoya University Hospitalhas a wealth of surgery record in various spinal cord diseases including spinal cord injury.In addition, it has strenuously advancedbasic research on the neuronalregeneration and achieved significant research results.GTS and Nagoya University agreed on the potential utility of SHED for a new therapyofspinal cord injury,resulting in thisjoint research agreement.

2.Outline of counterparty to this agreement

     1. Name    Nagoya University Hospital
     2. Location     65 Tsurumai-cho, Showa-ku, Nagoya
     3. Hospital Director     Yasuhiro Kodera
     4. Department     Neurosurgery

3.Future outlook

The impact on the business results for the fiscal year ending March 2020 is expected to be minimal.

About Gene Techno Science Co., Ltd.

GTS announced GTS 3.0 “Biotech Engineering Company, striving for value creation” a new business stage starting from this fiscal year, which targeted the pediatric disease in addition to the areas GTS has been engaged in such as the orphan disease and intractable disease. By leveraging the knowhow and expertise about biotechnology acquired in the past business activities, GTS is working on the development and provision of new medicines and therapeutic treatment for the purpose of achieving comprehensive healthcare solutions for the patients suffering from these diseases as well as families and caregivers.

Contact:

Gene Techno Science Co., Ltd.

Tel: +81-3-6222-9547

Mail: info@g-gts.com

To read more Press Release articles, click here.